N.J. Federal Dep-Medrol Case Dismissed; Plaintiff Permitted to Amend NJPLA Claims

CAMDEN, N.J. — A New Jersey federal judge has dismissed without prejudice a lawsuit alleging that Pfizer’s anti-inflammatory injectable, Dep-Medrol, was defectively designed and did not include adequate warnings, finding the claims were inadequately pled.

On Oct. 4, Judge Robert B. Kugler of the U.S. District Court for the District of New Jersey further found the plaintiffs failed to adequately plead their breach of warranty claim because it did not present an affirmation, promise, or description about Dep-Medrol.

Michael Sich visited Reconstructive Orthopedics, where a physician’s assistant administered an injection of Pfizer’s Dep-Medrol in his left knee. Later that month, …